ANANDA announces start of clinical trial for social anxiety treatment drug

Sohail R. Zaidi, Chief Executive Officer of ANANDA
Sohail R. Zaidi, Chief Executive Officer of ANANDA

ANANDA Scientific Inc., a research focused bio-pharmaceutical company announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in their proprietary Liquid Structure™ delivery tech as a potential treatment for Social Anxiety Disorder (SAD).

What are the key highlihghts of ANANDA’s clinical trial?

The National Center for Complimentary and Integrative Health (NCCIH) which is a division of the NIH, whose mission is to support key research about health products, is providing funding for this clinical trial which is being conducted at the NYU Grossman School of Medicine.

The trial is being led by the two Principal Investigators; Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at the acclaimed NYU Grossman School of Medicine.

This double-blind placebo-controlled clinical trial is studying NantheiaTM A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and an impact on a neuroimaging biomarker.

What are the executive remarks regarding the trial?

“We are very pleased to have this important clinical trial and study underway. Our collaboration with ANANDA is helping us complete our NIH funded research study of CBD, which is aimed at developing concrete scientific evidence about its mechanism and clinical effects to support the potential development of CBD as a new evidence-based treatment for Social Anxiety Disorder, a distressing and under-addressed, common mental health condition,” said Dr. Naomi Simon.

Dr. Blessing noted “preclinical results for CBD as a treatment for anxiety disorders show promising results and we look forward to building on these pre-clinical results in this study.”

“Enrolling the first subject in this important clinical trial is another key milestone for ANANDA’s clinical development program. We are very pleased to be collaborating with the NYU research team in evaluating our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need regarding social anxiety,” said Sohail R. Zaidi, ANANDA’s CEO.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.